Is It Still Safe To Buy AstraZeneca plc?

In this strong market, should you still buy AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

I’m always searching for shares that can help ordinary investors like you make money from the stock market. However, many people are currently worried the market has been overheating. 

So right now I’m analysing some of the most popular companies in the FTSE 100, hoping to establish if they can continue to outperform in today’s uncertain economy. 

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

Today I’m looking at pharmaceutical giant AstraZeneca (LSE: AZN) (NYSE: AZN.US) to determine whether the shares are still safe to buy at 3,139p.

So, how’s business going?

AstraZeneca has fallen out of favour with the market during last year or so, as investors become more anxious about the company’s future. 

In particular, investors are worried about the company’s impending ‘patent cliff’, as AstraZeneca is going to lose the exclusive manufacturing rights to three of its key treatments during the next three years, which combined represent about 45% of the company’s sales.  

Thankfully, with so much of the company’s sales under threat, management has been quick to enact a turnaround plan. 

Indeed, as part of its plan to return to health, AstraZeneca has announced that it is going to cut nearly 10% of its workforce.  In addition, the company has been searching for strategic acquisitions, recently spending around $2 billion on three small biotech companies all with their own treatments in the latter stages of development.

Furthermore, AstraZeneca is hardly running low on ideas itself, with a strong pipeline of 84 new treatments, 13 of which are in the final stages of coming to market.

Expected growth

Unfortunately, while the company works hard to turn itself around, patent expirations and falling sales will continue dent earnings for the next few years. City forecasts currently predict earnings of $5.62 per share for this year (a fall of 12%) and $4.96 for 2014. 

Shareholder returns

AstraZeneca is well known for its strong dividend, and it appears this payout is not going to stop anytime soon. Indeed, the company’s dividend is covered around two-and-a-half times by earnings, giving the company plenty of room to maintain or even increase the payout. 

In addition, AstraZeneca’s dividend yield is currently 5.8% — larger than that of its peers in the pharmaceutical sector, which currently offer an average dividend yield of 4.6%. 


Even though AstraZeneca is one of the largest biotechnology companies in the world, due to concerns over its future, the firm trades at a discount to its rivals. 

AstraZeneca currently trades at a historic P/E of 11, while its peers trade at an average historic P/E of around 15. 

Foolish summary

Overall, AstraZeneca is going to have a rough time during the next few years, as the company loses exclusive manufacturing rights to some of its key products. 

That said, the company is working hard to cut costs and has a full pipeline of new treatments in development. So, all in all, I believe that AstraZeneca still looks safe to buy at 3,139p.

More FTSE opportunities

As well as AstraZeneca, I am also positive on the five FTSE shares highlighted within this exclusive wealth report.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

In the meantime, please stay tuned for my next FTSE 100 verdict 

> Rupert does not own any share mentioned in this article.


Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

More on Investing Articles

Tired woman sleeping on London underground
Investing Articles

5 steps to monthly passive income streams of £500

Aiming for regular passive income streams, our writer walks through five key steps he would take.

Read more »

Business people shaking hands
Investing Articles

Director dealings: HSBC, National Grid, Taylor Wimpey

Director dealings can indicate whether a company's doing well. So, here are this week's director dealings from three of the…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

2 lesser-known stocks with 10% dividend yields!

With sky-high inflation, sizeable dividend yields can help my portfolio grow. These two stocks are paying 10% on average.

Read more »

Businessman pulling out wooden brick from toppling stack
Investing Articles

Is the Woodbois share price a bargain – or a value trap?

The Woodbois share price has seen big swings recently. Our writer considers why and explains his response.

Read more »

Electric cars charging in station
Investing Articles

Here’s why NIO stock is my top EV pick!

NIO stock had been one of the worst-performing shares over the last year, but it appears to have bottomed out.…

Read more »

Risk reward ratio / risk management concept
Investing Articles

The JD Wetherspoon share price has fallen 45% — should I load up?

The JD Wetherspoon share price has shed almost half its value in the past year. Should our writer buy another…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

Down 50%, is the Scottish Mortgage share price a bargain in plain sight?

The Scottish Mortgage share price has lost half its value in recent months. Is it now a bargain for our…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

A cheap UK share for the cybersecurity boom!

I'm backing this UK share after its share price collapsed this week. In fact, I've recently added this cybersecurity stock…

Read more »